We have some big news to share, and we’re glad you’re here to read about it!
Today, Cellero has announced that we will officially be joining Charles River.
This exciting change will complement Charles River’s recent acquisition of HemaCare and allow our company to better serve a growing list of customers and partners across the cell and gene therapy lifecycle. This unified value-added organization will enhance the supply of critical biomaterials, including a wide range of human-derived primary cell types to support the discovery, development, and manufacture of cell therapies.
Our mission is to help all of you — scientists, researchers, engineers, physicians, entrepreneurs — succeed in creating and administering tomorrow’s treatments and cures. Together we can help more people on their journeys to health and wellness.
We look forward to continuing to work with you to fuel your drug discovery and early-stage development needs.